/PRNewswire/ Protagonist Therapeutics (Nasdaq: PTGX) ("Protagonist" or "the Company") today reported financial results for the second quarter ended June 30,.
Though he was immensely wealthy he was reputed by fellow Declaration signers to be the richest among them, richer even than John Hancock he was a Catholic, and that made all the difference.
Stephen T. Sinatra, M.D., F.A.C.C., a board-certified cardiologist and certified psychotherapist with forty years of clinical experience treating, preventing
Rusfertide appeared to show robust activity in combination with standard therapies in treating polycythemia vera (PV) in patients with suboptimal erythrocytosis control.
Protagonist Therapeutics to Present Updated Phase 2 Rusfertide Clinical Results in Polycythemia Vera (PV) at ASCO 2022 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.